Our partners
Ten manufacturers across the United States, Europe, the United Kingdom, the GCC and inside the Kingdom have appointed us for this market. Each of them signs once, with one company that owns the registration, the warehouse, the cold chain and the fleet — and answers for all four.
What a partner gets
Market entry usually means assembling a consultant, an agent, a warehouse and a distributor, then hoping they agree on a date. This replaces all four.
The whole route sits under a single agreement: sourcing, SFDA registration, licensed storage, validated cold chain, sales and nationwide delivery. There is one company to call and one company to hold to a date.
Not a broker, not a freight agent, not a reseller. If a step in the route goes wrong, it goes wrong inside this company — where we can fix it.
Classification, registration strategy, dossier localisation, CTD and eCTD assembly, filing and listing are all done in-house. The team that files a dossier is the team that answers for the timeline.
Approval is not the end of it. Renewals, variations, line extensions and pharmacovigilance obligations stay with the same team. See the regulatory desk →
Before the first order, the market goes in writing: where the product fits, which audience it opens with, and what each phase of the launch requires.
Institutional first or retail first is a decision taken on paper, not discovered afterwards. Government and NUPCO, institutions, hospitals, pharmacies and retail are five different arguments, and we make the right one in the right room.
Licensed, GDP-aligned storage under SFDA licence WL-2023-DR-0043. Validated 2–8 °C cold chain. RSD batch traceability. More than eight owned vehicles, including cold-chain units.
Thirteen administrative regions, more than forty hospitals and medical cities, and 97% on-time delivery measured against an institutional KPI.
You have the product.
We have the Kingdom.
The manufacturers
Exclusive and selective agreements across the United States, Europe, the United Kingdom, the GCC and inside the Kingdom.
Every agreement below has the same shape: exclusive or selective terms for Saudi Arabia, SFDA registration owned by ATHEER PHARMA, storage in our licensed warehouse in Dammam, and delivery on our own fleet. We publish the manufacturer and the country; commercial terms stay in the contract.
This page carries no partner logos. We do not publish a manufacturer's mark without the right to use it.
A United Kingdom manufacturer under agreement for Saudi Arabia. Its lines are registered, stocked and delivered by us, under our own licence.
An Italian manufacturer under agreement for Saudi Arabia. One contract covers the route from registration through to delivery.
An Italian manufacturer under agreement for Saudi Arabia, supplied through the same licensed warehouse and fleet as every other line we hold.
A Belgian manufacturer under agreement for Saudi Arabia. Its Conceive Plus® brand is carried under the same relationship.
A SASMAR brand, distributed in Saudi Arabia by ATHEER PHARMA under our agreement with the manufacturer.
A SASMAR brandA Serbian manufacturer under agreement for Saudi Arabia — with the SFDA file owned here, not subcontracted.
A United Kingdom manufacturer under agreement for Saudi Arabia, with its registration prepared and maintained by our own regulatory team.
A GCC manufacturer, based in the United Arab Emirates, under agreement for Saudi Arabia.
A Portuguese manufacturer under agreement for Saudi Arabia, supplied under one licence from registration through to the delivery point.
A United States manufacturer under agreement for Saudi Arabia, reaching hospitals and pharmacies through the same single route.
Manufacturing inside the Kingdom. 5M produces our THERAVÉ® fertility sachets — Seminova and Ovabloom — to our specification.
Local manufacturingIf your product belongs in this market, the route already exists. We would rather tell you honestly what registration will take than sell you a date.
Talk to usThe market you are entering
It is a registration route, a licensed warehouse, thirteen administrative regions and a procurement system with its own rules. We already own that side of it.
Saudi pharmaceutical market, forecast for 2030
Hospitals and medical cities served directly
Administrative regions within delivery scope
On-time delivery against institutional KPI
People across regulatory, QA, sales and logistics
Made here
Importing is not always the right answer. We already manufacture inside Saudi Arabia: our own THERAVÉ® fertility sachets, Seminova and Ovabloom, are produced by 5M Pharmaceutical Industries to our specification.
THERAVÉ® is what we build when the market leaves a gap — fifteen SKUs across effervescent tablets, oral dissolving films and effervescent sachets, Halal certified and SFDA registered, moving through the same warehouse and the same fleet as every partner line we carry.
Ask for any of it to be evidenced — the licence, the temperature record, the KPI, the batch trace. Everything here is a document, not a claim.
Partner with us
Looking to enter
the Saudi market?
If you manufacture a product that belongs in this market, we provide the full route: regulatory strategy and SFDA registration through to nationwide sales, marketing and distribution — under one accountable name.
Start the conversation